

# DES Versus Bypass for Femoropopliteal Disease

Should the current data on drug-eluting devices cause surgeons to reconsider when to use bypass?

BY MARC BOSIERS, MD, AND KOEN DELOOSE, MD



Vascular surgeons have more options for treating femoropopliteal disease available today than ever before. Whereas other physician specialties only have to

consider the appropriateness of medical, exercise, and endovascular therapies for treating their patients, the vascular surgeon also has to consider bypass surgery. Good-quality randomized data comparing different endovascular options have significantly increased over the past decade. Among the different endovascular options, percutaneous transluminal angioplasty (PTA) and stenting are the most common and would have been considered standard care not too long ago.

The emergence of drug-coated balloons and drug-eluting stents, however, are now showing superiority to their bare counterparts. In the IN.PACT SFA trial, the In.Pact Admiral drug-coated balloon (Medtronic, Inc.) demonstrated superiority to a standard, bare PTA balloon catheter.<sup>1</sup> In the Zilver PTX randomized controlled trial, the Zilver PTX stent (Cook Medical) demonstrated superiority to both PTA and bare-metal stents (BMS).<sup>2</sup> These trials have given physicians great confidence in using drug-eluting devices over their bare counterparts.

A largely unanswered question, however, is how drug-eluting devices compare to bypass. Data comparing percutaneous coronary intervention/drug-eluting stents to coronary artery bypass grafting in the coronary arteries suggest that target lesion revascularization (TLR) rates are higher with percutaneous coronary intervention/drug-eluting stents, but the risk of stroke is higher with coronary artery bypass grafting.<sup>3,4</sup> Unfortunately, substantial data comparing femoropopliteal bypass to superficial femoral artery (SFA) drug-eluting stents are lacking.

In the BASIL trial, bypass was compared to PTA. For the first 2 years of follow-up, there was no difference between PTA and bypass; but after 2 years, bypass showed more durable results.<sup>5</sup> Although the trial pro-

---

When considering performance in randomized trials, safety issues, and the cost of each device, a strong hypothesis may be formed in favor of Zilver PTX.

---

vided some insight into the performance of bypass compared to PTA, it is greatly limited for drawing conclusions about choosing modern SFA treatment options. The evidence comparing drug-eluting therapies to bypass is far from complete, but there is some evidence available to help surgeons re-examine their treatment philosophies and consider whether they should make any adjustments to how they approach treatment selection for SFA lesions. This article examines how drug-eluting SFA stents compare to three forms of bypass: “endovascular bypass” (polytetrafluoroethylene stent grafts), synthetic bypass, and vein bypass.

## ZILVER PTX VERSUS ENDOVASCULAR BYPASS

Although femoropopliteal stent grafts are not technically a mode of bypass, some vascular surgeons choose them based on their perceived similarities to synthetic bypass. The most widely used femoropopliteal stent graft is the Viabahn endoprosthesis (Gore & Associates). Currently, there are no head-to-head data comparing Zilver PTX to the Viabahn device, but there are some good randomized data for each device. From these data, we may be able to formulate hypotheses about which device to choose.

The Viabahn device was randomized against BMS in two different trials: the VIBRANT trial and, most recently, the VIASTAR trial. In the VIBRANT trial, the first-generation Viabahn device did not demonstrate a difference in patency when compared to BMS (24.2%

vs 25.9% at 3 years, respectively). However, the second-generation Viabahn fared better than the first-generation device. In the VIASTAR trial, Viabahn showed an improvement in patency to a BMS at 24 months (63.3% vs 41.4%).<sup>6</sup> That said, the primary patency results were somewhat dampened by the secondary patency rates and freedom from TLR rates. Viabahn showed no significant improvement over BMS for secondary patency (89.7% vs 88.8%) and no significant improvement in freedom from TLR at 24 months (76.1% vs 68.4%).<sup>6</sup> Regardless of which device generation is used, the benefit of Viabahn over BMS appears to be marginal.

In the Zilver PTX randomized trial, the Zilver PTX device showed significant improvement over both optimal PTA and BMS, cutting both restenosis and reinterventions by nearly half. At 2 years, Zilver PTX showed a 46% reduction in restenosis (83.4% vs 63.1%).<sup>2</sup> Further, Zilver PTX demonstrated a 53% reduction in reinterventions at the 2-year mark (89.1% vs 76.7%).

In addition to considerations of effectiveness, one must consider safety factors, as well. Thrombosis can be a challenge for permanently implanted devices. However, Zilver PTX showed a 2.3% thrombosis rate through 2 years compared to the BMS rate of 3.6%.<sup>7</sup> Further, a scan of the literature shows that a thrombosis rate of 2% to 5% is typical for bare-metal SFA stents and that Zilver PTX is within that range. Although Viabahn has shown modest acute thrombosis rates, it has not fared as well in terms of late stent thrombosis. In the Viabahn 25-cm study, Gore reports that the latest generation of Viabahn has a 12-month thrombosis rate of 15.5%.<sup>8</sup> In one physician-initiated study, thrombosis rates through 12 months were reported to be at 17%.<sup>9</sup> Further, that same study reports that 12% of patients undergoing Viabahn placement presented with acute limb ischemia.

When considering performance in randomized trials, safety issues, and the cost of each device, a strong hypothesis may be formed in favor of Zilver PTX.

### ZILVER PTX VERSUS SYNTHETIC BYPASS

Before assessing differences between an endovascular device trial to a surgical bypass trial, one must account

for the historically different definitions of patency between the two. Importantly, one should take note that bypass patency is not the same as endovascular patency. In an endovascular trial, such as the Zilver PTX randomized trial, patency is often measured in a binary fashion and is determined by the patient's peak systolic velocity ratio (PSVR) relative to the PSVR threshold set in the trial design (usually 2.0 or 2.4). By contrast, bypass is assessed simply by observing the flow through the bypass: either it is open or closed.

In a recent prospective study, Deloose et al found that 11% of those considered to be patent by classic vascular definitions were restenosed when using an endovascular standard of binary restenosis at a PSVR of 2.4.<sup>10</sup> Therefore, comparing patency between surgical and endovascular trials handicaps any endovascular therapy (especially if a more conservative PSVR of 2.0 is used).

Although there are no completed trials directly comparing Zilver PTX to bypass, data from various randomized controlled trials can help formulate hypotheses about which one might perform better (Table 1). A selective scan from 2005 to 2010 of trials that include bypass primary patency showed a 12-month primary patency rate of between 70% and 80%.<sup>11</sup> For the Zilver PTX randomized trial, single-arm study, and Japanese postmarket surveillance study, the 12-month primary patency rates for Zilver PTX ranged from 80% to 90%. A comprehensive literature review of bypass trials from 1966 to 2002 shows that the 2-year patency rate for synthetic bypass was 67%.<sup>12</sup> Results from the Zilver PTX randomized trial show that the primary patency rate at 2 years was 83.4%. It will be interesting to see how the 5-year patency rate for Zilver PTX compares to the 5-year patency rates for synthetic bypass.

Obviously, the most reliable method of comparison would be to randomize patients to either bypass or Zilver PTX in the same trial. By conducting a head-to-head comparison of Zilver PTX to bypass in the same trial, the patency bias that was previously discussed will be eliminated. That is why this author has initiated the ZILVERPASS study. The study will include two arms with a 1:1 randomization to either Zilver PTX or synthetic

**TABLE 1. COMPARISON OF PATENCY RATES BY PROCEDURAL MODALITY**

Treatment Type	2-Year Patency	4-Year Patency	5-Year Patency
Synthetic bypass	67%	NA	49%
Vein bypass	80%	NA	69%
Zilver PTX	83%	75%	NA (data will be reported later this year)
Abbreviation: NA, not available.			

bypass. Further, as previously noted, the definition of patency will be the same for both arms, giving us one of the best comparisons of Zilver PTX to synthetic bypass to date. The trial is currently in the process of enrolling, and we look forward to seeing these data, which will inform treatment options for vascular surgeons.

## ZILVER PTX VERSUS VEIN BYPASS

For most vascular surgeons, vein bypass is the gold standard for treating the femoropopliteal segment. But given the aforementioned differences between how patency is measured for a surgical bypass trial and an endovascular trial, comparisons can be difficult to assess. Nonetheless, there are some data available to again help us formulate hypotheses about the relative effectiveness of femoropopliteal bypass compared to SFA drug-eluting stents.

The same comprehensive literature review of bypass trials from 1966 to 2002 (as previously mentioned) shows the 2-year patency rate for vein bypass at 80%.<sup>12</sup> Results from the Zilver PTX randomized trial demonstrated a 2-year primary patency rate of 83%. From the same literature review of multiple bypass trials, the aggregated 5-year patency rate for vein bypass was 69%. The 4-year primary patency rate for Zilver PTX was 75%. We look forward to the publication of the 5-year Zilver PTX RCT data.

The ZILVERPASS study, comparing head-to-head bypass versus Zilver PTX for above-the-knee long femoropopliteal lesions, will shed new light on how the next long overdue revision of the TASC classification should be handled. ■

*Marc Bosiers, MD, is Chief of Surgery at AZ Sint-Blasius in Dendermonde, Belgium. He stated that he has no financial interests related to the article. Dr. Bosiers may be reached at marc.bosiers@telenet.be.*

*Koen Deloose, MD, is a vascular surgeon at AZ Sint-Blasius in Dendermonde, Belgium. He stated that he has no financial interests related to the article.*

*Neither Dr. Bosiers nor Dr. Deloose were paid for writing this article.*

1. IN.PACT SFA one-year results: Drug-eluting balloon outperforms angioplasty with lower reintervention rates and superior patency. Charing Cross website. <http://www.cxvascular.com/cx-latest-news/cx-latest-news/cx-2014-audience-recognises-the-impact-of-drug-eluting-balloons>. Accessed September 15, 2014.
2. Dake MD, Ansel GM, Jaff MR, et al. Sustained safety and effectiveness of paclitaxel-eluting stents for femoropopliteal lesions: 2-year follow-up from the Zilver PTX randomized and single-arm clinical studies. *J Am Coll Cardiol*. 2013;61:2417-2427.
3. Athappan G, Patvardhan E, Tuzcu ME, et al. Left main coronary artery stenosis: a meta-analysis of drug-eluting stents versus coronary artery bypass grafting. *JACC Cardiovasc Interv*. 2013;6:1219-1230.
4. Al Ali J, Franck C, Filion KB, Eisenberg MJ. Coronary artery bypass graft surgery versus percutaneous coronary intervention with first-generation drug-eluting stents: a meta-analysis of randomized controlled trials. *JACC Cardiovasc Interv*. 2014;7:497-506.
5. Conte MS. Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia. *J Vasc Surg*. 2010;51(5 suppl):69S-75S.
6. Lammer J. Endovascular treatment of TASC C and D lesions in the SFA 2 year data of the VIASTAR trial. Presented at ISET 2014; January 18–22, 2014; Miami Beach, FL.
7. Zilver PTX Instructions for Use. Cook Medical website. [https://www.cookmedical.com/data/IFU\\_PDF/IFU0093-4.PDF](https://www.cookmedical.com/data/IFU_PDF/IFU0093-4.PDF). Accessed September 15, 2014.
8. Instructions for Use for Gore Viabahn endoprosthesis. Gore Medical website. <http://www.goremedical.com/resources/dam/assets/20019563.pdf>. Accessed September 15, 2014.
9. Johnston PC, Vartanian SM, Runge SJ, et al. Risk factors for clinical failure after stent graft treatment for femoropopliteal occlusive disease. *J Vasc Surg*. 2012;56:998-1006.
10. Deloose K, Bosiers M, Callaert J, et al. Evaluation of primary patency in surgical bypasses using the endovascular approach. Presented at Eastern Vascular Society 26th Annual Meeting; September 13–15, 2012; Pittsburgh, PA. Available at <http://meeting.easternvascular.org/abstracts/2012/p17.cgi>. Accessed September 15, 2014.
11. Bosiers M. Does Zilver PTX DES yield better results than an open bypass? Presented at Controversies & Updates in Vascular Surgery; January 23–25, 2014; Paris, France.
12. Klinkert P, Post PN, Breslau PJ, van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. *Eur J Vasc Endovasc Surg*. 2004;27:357-362.

INDICATIONS: indicated for improving luminal diameter for the treatment of de novo or restenotic symptomatic lesions in native vascular disease of the above-the-knee femoropopliteal arteries having reference vessel diameter from 4mm to 7mm and total lesion lengths up to 140 mm per limb and 280 mm per patient. CONTRAINDICATIONS: Women who are pregnant, breastfeeding, or plan to become pregnant in the next 5 years should not receive a Zilver PTX Drug-Eluting Peripheral Stent. Patients who cannot receive recommended anti-platelet and/or anti-coagulant therapy. Patients judged to have a lesion that prevents proper placement of the stent or stent delivery system. WARNINGS: Persons with allergic reactions to nitinol may suffer an allergic reaction to this implant? Persons allergic to paclitaxel may suffer an allergic reaction to this implant? The safety and effectiveness of implanting more than four Zilver PTX Drug Eluting Peripheral Stents in a patient has not been clinically evaluated. PRECAUTIONS: To avoid involvement of the common femoral artery, the proximal end of the stent should be placed at least 1 cm below the origin of the superficial femoral artery. To avoid involvement of the below-the-knee popliteal artery, the distal end of the stent should be placed above the plane of the femoral epicondyles. This product is intended for use by physicians trained and experienced in diagnostic and interventional vascular techniques. Standard techniques for interventional vascular procedures should be employed. Manipulation of the Zilver PTX Drug-Eluting Peripheral Stent requires fluoroscopic control. Do not try to remove the stent from the introducer system before use. Ensure that the red safety lock is not inadvertently removed until final stent release. Deploy the stent over an extra stiff or ultra stiff wire guide. Do not push the hub toward the handle during deployment. Do not expose the delivery system to organic solvents (e.g., alcohol). Do not use power injection systems with the delivery system. Do not rotate any part of the system during deployment. The device is intended for single use only. Do not resterilize and/or reuse this device. Repositioning of the device after deployment is not possible since the introducer catheter cannot be re-advanced over the stent once deployment begins. POTENTIAL ADVERSE EVENTS: Potential adverse events that may occur include, but are not limited to Allergic reaction to anticoagulant and/or antithrombotic therapy or contrast medium. Allergic reaction to nitinol. Arterial aneurysm. Arterial rupture. Arterial thrombosis. Arteriovenous fistula. Atheroembolization (Blue Toe Syndrome). Death. Embolism. Hematoma/hemorrhage. Hypersensitivity reactions. Infection. Infection/abscess formation at access site. Ischemia requiring intervention (bypass or amputation of toe, foot or leg). Pseudoaneurysm formation. Renal failure. Restenosis of the stented artery. Stent embolization. Stent malapposition. Stent migration. Stent strut fracture. Vessel perforation or rupture. Worsened claudication/rest pain. Paclitaxel: Although systemic effects are not anticipated, refer to the Physicians' Desk Reference for more information on the potential adverse events observed with paclitaxel. Potential adverse events, not described in the above source, may be unique to the paclitaxel drug coating, including. Allergic/immunologic reaction to the drug coating. Alopecia. Anemia. Blood product transfusion. Gastrointestinal symptoms. Hematologic dyscrasia (including leukopenia, neutropenia, thrombocytopenia). Hepatic enzyme changes. Histologic changes in vessel wall, including inflammation, cellular damage, or necrosis. Myalgia/Arthralgia. Myelosuppression. Peripheral neuropathy. See package insert for full product information.